Future savings from measles eradication in industrialized countries

Journal of Infectious Diseases

Volumn 187, Issue SUPPL. 1, 2003, Pages

  Carabin, Hélène ^a,b   Edmunds, W John ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE;

ARTICLE; BIOLOGICAL WARFARE; CANADA; COST CONTROL; DRUG COST; ERADICATION THERAPY; EUROPE; HUMAN; INDUSTRIALIZATION; MEASLES; MEASLES VACCINATION; PRIORITY JOURNAL; UNITED STATES; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

CANADA; DEVELOPED COUNTRIES; EUROPE; HUMANS; MASS IMMUNIZATION; MEASLES; MEASLES VACCINE; MEASLES-MUMPS-RUBELLA VACCINE; MODELS, ECONOMIC; VACCINATION;

EID: 0037648548     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368038     Document Type: Article

References (23)

1. Department of Vaccines and Biologicals, World Health Organization, United Nations Children's Fund. Global measles mortality reduction and regional elimination. Strategic plan 2001-2005. Geneva: WHO, 2001 (V&B/WHO/01.15).
2. Miller MA, Redd S, Hadler S, Hinman A. A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine 1998; 16:1917-22.
3. Wallinga J, Lévy-Bruhl D, Gay NJ, Wachmann CH. Estimation of measles reproduction ratios and prospects for elimination of measles by vaccination in some western European countries. Epidemiol Infect 2001; 127:281-95.
4. De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible disease after elimination. Am J Epidemiol 2000; 151:1039-48.
5. Pachon del Amo I. Situación del sarampión en España. Estudio seroepidemiológico. Rev Esp Salud Publica 1999; 73:609-16.
6. Carabin H, Edmunds WJ, Kou U, Van den Hof S, Hung Nguyen VH. The average cost of measles cases and adverse events following vaccination in industrialized countries. BMC Public Health 2002; 2:22. Available at: http://www.biomedcentral.com/1471-2458/2/22.
7. Bentsi-Enchill A, Varughese, P. Current status of measles in Canada: provisional report (as of 10 December 1999). Update: vaccine-preventable diseases. Ottawa: Health Canada, 2000:3.
8. Notifiable diseases summary 2000. Can Commun Dis Rep 2002; 28:50-2.
9. Centro Nacional de Epidemiologia, Instituto de Salud Carlos III Ministerio de Salidad y Consumo. Measles incidence and MMR coverage in Spain, 2001. Available at: http://193.146.50.130/bienve.htm.
10. Public Health Laboratory Services (PHLS). Measles incidence and MMR coverage in the UK. London: PHLS, 2001. Available at: http://www.phls.org.uk/.
11. Swedish Institute for Infectious Disease Control. Smittskyddsinstitutet. Communicable diseases annual reports. Available at: http://www.smittskyddsinstitutet.se.
12. van den Hof S, Meffre CME, Conyn-van Spaendonck MAE, Woonink F, Melker HE de, van Binnendijk RS. Measles outbreak in a community with very low vaccine coverage, the Netherlands. Emerg Infect Dis 2001; 7:593-7.
13. Statens Serum Institute. Incidence of measles in Denmark. Available at: http://www.ssi.dk.
14. Institute of Health Economics. A national list of provincial costs for health costs: 1997/8. Edmonton, Canada: Institute of Health Economics, 2000.
15. Netten A, Curtis L. Unit costs for health and social care 2000. Canterbury, UK: Personal Social Services Research Unit, 2000.
16. Consejo General de Colegios de Farmaceuticos de Espana. Base de datos del medicamento, 2002. Available at: http://www.portalfarma.com/home.nsf.
17. Fescharek R, Quast U, Maass G, Merkle W, Schwarz S. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects. Vaccine 1990; 8:446-56.
18. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45(RR-12):1-35.
19. Bentsi-Enchill A, Hardy M, Koch J, Duclos P. Adverse events temporally associated with vaccines - 1992 report. Can Commun Dis Rep 1995; 21:117-28.
20. Ros CC, Groenewegen PP, Delnoij DMJ. All rights reserved, or can we just copy? Cost sharing arrangements and characteristics in health care systems. Health Policy 2000; 52:1-13.
21. Lankinen KS. Scientific and technical evaluation of vaccination programmes in the European Union. In: Lankinen KS, ed. EUVAX project report. Helsinki: PSR Consulting, 2001.
22. Organisation for Economic Co-Operation and Development (OECD). Health data 2001. Paris: OECD, 2001.
23. @Risk. Risk analysis and simulation add-in for Excel. New York: Palisade, 2000.